Vivo Capital Fund IX, L.P.'s Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed May 5, 2022
- Accession no.
- 0001213900-22-024317
- Filed
- May 5, 2022, 6:55 PM ET
- Trade date
- May 5, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $65.8K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vivo Capital Fund IX, L.P.CIK 0001750117 | 10% Owner |
| Vivo Capital IX, LLCCIK 0001750698 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 5, 2022 | Common Stock | SSaleDisposed | −5,374 | $12.25F1 | −$65,831.5 | 2,469,001 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.33, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.